Company Overview
Veru Inc. operates as a late clinical stage biopharmaceutical company dedicated to the development of therapeutic medicines targeting metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome, with operational activities conducted in Florida and internationally. The company functions within the broader healthcare sector, specifically inside the biotechnology industry, which implies a focus on high-risk, high-reward research and development cycles aimed at bringing novel treatments to market. The organization maintains a compact operational scale with a market capitalization of $33.55M and an employee count of 20 individuals. These financial and structural metrics indicate that Veru is a small-cap entity with limited revenue generation capabilities, suggesting it is in an early commercialization phase where capital is primarily allocated to advancing clinical trials rather than generating significant sales volume or profitability.
Financial Health
The company reports N/A for annual revenue over the trailing twelve-month period, while recording a net loss of $-19,203,932 and an EBITDA of $-29,895,576. The substantial gap between the reported revenue of N/A and the significant net income loss of $-19,203,932 reveals a cost structure dominated by research and development expenditures that far exceed current income generation. Free cash flow stands at $-11,035,380, which indicates that the company is consuming cash reserves to fund its operations and development pipeline rather than generating liquidity for shareholder returns. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, indicating that the company has not yet achieved positive gross profitability or operating leverage to convert revenue into profit. On the balance sheet, the company holds $35.30M in cash against $2.98M in debt, resulting in a debt-to-equity ratio of 8.02, which suggests a leveraged position where equity capital is used to support a debt load that is disproportionately high relative to shareholder equity. Despite the high debt-to-equity figure, the current ratio is 5.16, indicating that the company possesses strong short-term liquidity as it holds significantly more current assets than current liabilities. Return on Equity is -60.2% and Return on Assets is -42.9%, metrics that reveal management is currently unable to generate positive returns on the capital invested in the business or the assets owned.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is listed as -1.74, implying that the market is pricing in expected future losses rather than current profitability. The price-to-book ratio is 0.90, which indicates that the market values the company at 90% of its book value, suggesting the stock is trading at a discount relative to its tangible asset base. The price-to-sales ratio is N/A because the company has not generated sufficient sales to calculate a meaningful multiple, and the EV/EBITDA stands at -0.04, reflecting a valuation framework where enterprise value is barely above negative earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $7.40 and a 52-week low of $2.06, and without a specific current price provided in the data, the valuation is best understood by this historical volatility range. The beta value is -1.45, which is an anomalous negative coefficient indicating that the stock price has historically moved in the opposite direction of the broader market with high intensity, resulting in extreme price volatility relative to the standard market benchmark.
Growth & Income
Revenue growth and earnings growth are both listed as N/A, meaning there is no historical data available to determine if earnings are growing faster or slower than revenue, nor can a trend be established from the current fiscal snapshot. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that the company retains all available earnings to reinvest into growth initiatives rather than distributing income to shareholders. Given the negative net income and zero profit margins, the payout ratio of 0.0% is structurally unsustainable as a dividend policy but is consistent with a capital preservation strategy typical for loss-making biotechnology firms. The overall growth and income profile for Veru Inc. is characterized by a complete absence of current profitability, dividend income, or verifiable growth rates, reflecting the speculative nature of a late-stage clinical company focused on future drug approvals rather than immediate financial returns.